Medindia
Medindia LOGIN REGISTER
Advertisement

Novartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data

Wednesday, September 13, 2017 General News
Advertisement
- Cosentyx® (secukinumab) is the first and only fully human IL-17A antagonist to show sustained skin clearance rates at 5 years in Phase III in psoriasis(1)

Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: [email protected]

Central

North America

Samir Shah

+41 61 324 7944

Richard Pulik

+1 212 830 2448

Pierre-Michel Bringer

+41 61 324 1065

Cory Twining

+1 212 830 2417

Thomas Hungerbuehler

+41 61 324 8425

Isabella Zinck

+41 61 324 7188

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close